Literature DB >> 11604398

Parathyroid hormone (PTH)-(1-14) and -(1-11) analogs conformationally constrained by alpha-aminoisobutyric acid mediate full agonist responses via the juxtamembrane region of the PTH-1 receptor.

N Shimizu1, J Guo, T J Gardella.   

Abstract

The N-terminal portion of parathyroid hormone is critical for PTH-1 receptor (P1R) activation and has been postulated to be alpha-helical when bound to the receptor. We investigated whether substitution of the sterically hindered and helix-promoting amino acid alpha-aminoisobutyric acid (Aib) in N-terminal PTH oligopeptides would improve the capacity of the peptide to activate the P1R. Analysis of the effects of individual Aib substitutions at each position in [Ala(3,12),Gln(10),Har(11),Trp(14)]PTH(1-14)NH(2) ([M]PTH(1-14)) on cAMP-stimulating potency in HKRK-B28 cells revealed that Aib at most positions diminished potency; however, Aib at positions 1 and 3 enhanced potency. Thus [Aib(1,3),M]PTH(1-14) was approximately 100-fold more potent than [M]PTH(1-14) (EC(50) = 1.1 +/- 0.1 and 100 +/- 20 nm, respectively), approximately 100,000-fold more potent than native PTH(1-14), and 2-fold more potent than PTH(1-34). The shorter peptide, [Aib(1,3),M]PTH(1-11), was also fully efficacious and 1,000-fold more potent than [M]PTH(1-11) (EC(50) 4 +/- 1 nm versus 3 +/- 1 microm). In cAMP stimulation assays performed in COS-7 cells expressing P1R-delNt, a receptor that lacks most of the N-terminal extracellular domain, [Aib(1,3),M]PTH(1-14) was 50-fold more potent than [M]PTH(1-14) (EC(50) = 0.7 +/- 0.2 versus 40 +/- 2 nm) and 1,000-fold more potent than PTH(1-34) (EC(50) = 700 nm). [Aib(1,3),M]PTH(1-14), but not PTH(1-34), inhibited the binding of (125)I-[Aib(1,3),Nle(8),Gln(10),Har(11),Ala(12),Trp(14),Arg(19),Tyr(21)]PTH(1-21)NH(2) to hP1R-delNt (IC(50) = 1,600 +/- 200 nm). The Aib(1,3) substitutions in otherwise unmodified PTH(1-34) enhanced potency and binding affinity on hP1R-delNt, but they had no effect for this peptide on hP1R-WT. Circular dichroism spectroscopy demonstrated that the Aib-1,3 substitutions increased helicity in all peptides tested, including PTH(1-34). The overall data thus suggest that the N-terminal residues of PTH are intrinsically disordered but become conformationally constrained, possibly as an alpha-helix, upon interaction with the activation domain of the PTH-1 receptor.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11604398     DOI: 10.1074/jbc.M106827200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  19 in total

Review 1.  Structure and mechanism for recognition of peptide hormones by Class B G-protein-coupled receptors.

Authors:  Kuntal Pal; Karsten Melcher; H Eric Xu
Journal:  Acta Pharmacol Sin       Date:  2012-01-23       Impact factor: 6.150

2.  Turn-on switch in parathyroid hormone receptor by a two-step parathyroid hormone binding mechanism.

Authors:  Marián Castro; Viacheslav O Nikolaev; Dieter Palm; Martin J Lohse; Jean-Pierre Vilardaga
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-18       Impact factor: 11.205

3.  'Partial' competition of heterobivalent ligand binding may be mistaken for allosteric interactions: a comparison of different target interaction models.

Authors:  Georges Vauquelin; David Hall; Steven J Charlton
Journal:  Br J Pharmacol       Date:  2015-03-17       Impact factor: 8.739

4.  Structure and dynamics of the active human parathyroid hormone receptor-1.

Authors:  Li-Hua Zhao; Shanshan Ma; Ieva Sutkeviciute; Dan-Dan Shen; X Edward Zhou; Parker W de Waal; Chen-Yao Li; Yanyong Kang; Lisa J Clark; Frederic G Jean-Alphonse; Alex D White; Dehua Yang; Antao Dai; Xiaoqing Cai; Jian Chen; Cong Li; Yi Jiang; Tomoyuki Watanabe; Thomas J Gardella; Karsten Melcher; Ming-Wei Wang; Jean-Pierre Vilardaga; H Eric Xu; Yan Zhang
Journal:  Science       Date:  2019-04-12       Impact factor: 47.728

5.  Actions of the small molecule ligands SW106 and AH-3960 on the type-1 parathyroid hormone receptor.

Authors:  Percy H Carter; Thomas Dean; Brijesh Bhayana; Ashok Khatri; Raj Rajur; Thomas J Gardella
Journal:  Mol Endocrinol       Date:  2015-01-13

Review 6.  Cell membranes… and how long drugs may exert beneficial pharmacological activity in vivo.

Authors:  Georges Vauquelin
Journal:  Br J Clin Pharmacol       Date:  2016-05-29       Impact factor: 4.335

7.  Different domains of the glucagon and glucagon-like peptide-1 receptors provide the critical determinants of ligand selectivity.

Authors:  S Runge; B S Wulff; K Madsen; H Bräuner-Osborne; L B Knudsen
Journal:  Br J Pharmacol       Date:  2003-03       Impact factor: 8.739

8.  Altered selectivity of parathyroid hormone (PTH) and PTH-related protein (PTHrP) for distinct conformations of the PTH/PTHrP receptor.

Authors:  Thomas Dean; Jean-Pierre Vilardaga; John T Potts; Thomas J Gardella
Journal:  Mol Endocrinol       Date:  2007-09-13

9.  Agonist-regulated cleavage of the extracellular domain of parathyroid hormone receptor type 1.

Authors:  Christoph Klenk; Stefan Schulz; Davide Calebiro; Martin J Lohse
Journal:  J Biol Chem       Date:  2010-01-15       Impact factor: 5.157

10.  Allosteric modulators of class B G-protein-coupled receptors.

Authors:  Sam R J Hoare
Journal:  Curr Neuropharmacol       Date:  2007-09       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.